Investment
Features
FeesSafety
Academy
More
Pluang+

GPT-6 Astra and GPT-6.1 Sol now run 50% faster, boosting AI app performance and cutting costs.

Protocol Fundamentals
05 Oct 2026
Crypto Briefing
View Source
Bullish
GPT-6 Astra and GPT-6.1 Sol now run 50% faster, boosting AI app performance and cutting costs.

OpenAI has increased the speed of its GPT-6 Astra and GPT-6.1 Sol models by 50% across products using Sign in with ChatGPT, improving response times in third-party apps. GPT-6.1 Sol offers nearly the same performance as Astra but at one-fifth the cost, making advanced AI more accessible to small businesses and developers. This speed and cost improvement could drive higher adoption of AI technologies and create new opportunities for investors. Users should notice faster responses in apps using these models.

The GPT-6 Astra and GPT-6.1 Sol speed improvements provide context for digital innovation trends. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 06, 2026 00:32 WIB: 22 of 50 major cryptocurrencies rose while 27 fell. ZIL gained 2.78% to Rp64 with 100% buy order activity, KSM dropped 2.75% to Rp90,852 with 89% sell orders, and AAVE increased 2.63% to Rp3,298,886 with a typical hold time of 105 days.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
29 minutes ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
1 hour ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
2 hours ago
NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...

Analyst Insights
Bullish
3 hours ago
Fidelity National Financial to report Q3 2026 earnings on Nov 5 with webcast and call on Nov 6

Fidelity National Financial to report Q3 2026 earnings on Nov 5 with webcast and call on Nov 6

Fidelity National Financial, a leading title insurance and insurance solutions provider, will release its third quarter 2026 earnings after market close on November 5, 2026. The company will hold a webcast and conference call at 11:00 a.m. Eastern Ti...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App